European Commission approves Roche Tecentriq joint amatin and chemotherapy for first-line treatment in adult patients with non-small cell lung cancer

recently, Roche, the swisspharmaceutical(http://giant, announced that the European Commission (EC) has approved the PD-L1 tumor immunotherapy tecentriq (atezolizumab) combined with Avastin (generic name: bevacizumab, bevala monoantigen) and chemotherapy (sequoia alcohol and caplatinum) for the treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSQ)For Patients with EGFR mutation synome or ALK-positive NSCLC, tecentriq combined with Avastin and chemotherapy (purple sequoia and caplatin) program only applies to patients after failure to receive appropriate targeted therapy treatmentin the United States, Tecentriq, a triple program, was approved in December 2018 for first-line treatment in adult patients withno EGFR or ALK genomic tumor distortion metastatic NSq NSCLCThe studythe approval of tecentriq and Avastin and chemotherapy (purple sequoia and caplatinum) triple program, based on data from phase III clinical study IMpower150 (NCT02366143)this study is a multicenter, open label, randomized, controlled study conducted in patients with stage IV or recurrent NSq NSCLC who have not previously undergone chemotherapy to control advanced disease, and evaluated the efficacy and safety of Tecentriq's combination with chemotherapy (purple sequoia and cacrel) or non-use of Avastin for first-line therapystudy included 1,202 patients, 1,045 of whom were patients in the intent treatment wild type (ITT-WT) subgroup, who excluded EGFR and ALK mutationsIn the study, patients were randomly enrolled in three treatment groups with a ratio of 1:1:1: Group A (Tecentriq plus chemotherapy), Group B (Tecentriq and Avastin plus chemotherapy), and Group C (Avastin-chemotherapy)The common primary endpoint of the study was a comparison of total survival (OS) and non-progressive survival (PFS) in itT-WT subgroup patients assessed by the researchers using the solid tumor efficacy evaluation criteria 1.1 (RECIST v1.1)Key secondary endpoints include PFS, OS, and security assessed by researchers in the ITT groupThe results showed that in the active treatment wild type (ITT-WT) subgroup: tecentriq and Avastin-chemotherapy programme significantly extended OS (median OS: 19.8 months vs14.9 months, HR-0.76,95%CI: 0.63-0.96, p-0.006) compared to Avastin-Avastin-Chemotherapy ), significantly reduced the risk of disease progression or death by 41% (HR: 0.59, 95% CI: 0.50-0.69, p 0.0001), reduced tumor volume (total remission rate : 56.4% vs 40.2%), extended mitigation duration (median DoR: 11.5 months vs 6.0 months)instudy, tecentriq's combined drug safety was consistent with previous studies and found no new safety signals 　　About Tecentriq
Teciq belongs to PD-(L)1 tumor immunotherapy, a high-profile type of tumor immunotherapy designed to use the body's own immune system to fight cancer, by blocking the PD-1/PD-L1 signaling pathway to kill cancer cells, with the potential to treat a variety of types of tumors to date, Tecentriq has been approved by more than 80 countries worldwide: (1) for patients with metastatic NSCLC with no metastatic defection stolicorof of EGFR or ALK tumor genome during or after platinum chemotherapy, (2) for patients with late or metastatic urinary disease (mUC) who are not suitable for treatment of cplatin chemotherapy or during or after platinum chemotherapy in the United States, Tecentriq's combined Avastin and chemotherapy triple program was approved in December 2018 for first-line treatment of metastatic NSq NSCLC adult patients without EGFR or ALK genomic tumor distortion